By Katherine Hamilton
A court ruled in favor of Acadia Pharmaceuticals in its litigation alleging patent infringement.
Acadia had alleged certain abbreviated new drug application filers, including Aurobindo Pharma, had committed formulation patent infringement of its drug Nuplazid.
A Delaware district court ruled in favor of Acadia's infringement and validity arguments. The ruling provides patent protection for Nuplazid formulation, Chief Executive Catherine Owen Adams said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
May 16, 2025 14:24 ET (18:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.